Live Breaking News & Updates on வளர்சிதை மாற்ற தகவல்தொடர்புகள்

Posted December 16th, 2020 for Novartis
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening blood disorder, resulting in debilitating symptoms that can impact patients’ quality of life
1–3
C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need
4-5
With potential to be the first oral treatment for a range of complement-driven diseases, complement factor B inhibitor iptacopan targets the underlying cause of these conditions through its action on the complement system’s alternative pathway
6,7
Iptacopan is in development for PNH, as well as C3G and several other rare renal diseases including IgA nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and membranous nephropathy (MN); first FDA filings anticipated in 2023 ....

United States , Eric Althoff , Isabella Zinck , Samir Shah , Thomas Hungerbuehler , Phil Mcnamara , Sloan Simpson , Nephrol Hypertens , Drug Administration , Novartis Oncology Communications , International Paroxysmal Nocturnal Hemoglobinuria Registry , Novartis Us External Communications , Exchange Commission , European Society For Blood , Meeting Of The American Society Nephrology , Metabolic Communications , European Medicines Agency , Breakthrough Therapy Designation , Rare Pediatric Disease , European Society , Marrow Transplantation , American Society , International Paroxysmal Nocturnal Hemoglobinuria , Accessed September , Improving Global , Accessed December ,